Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy

Summary

Cerebral hemorrhage, as a serious cerebrovascular disease, has the highest disability rate and mortality rate among all types of cerebrovascular diseases .It has brought a heavy burden to society. In China, the incidence of cerebral hemorrhage is much higher than that in Europe and America, and cerebral amyloid angiopathy (CAA) is one of the causes of primary cerebral hemorrhage However, there are relatively few related studies. Therefore, the research object of this subject focuses on patients with cerebral amyloid angiopathy, in view of their high recurrence rate of vascular events and the lack of treatment methods.It aims to deeply explore the detoxification and blood stasis removal treatment plan combining traditional Chinese and Western medicine to reduce vascular events for patients.

Conditions

• Cerebral Amyloid Angiopathy

Interventions

DRUG

Jiedu Huayu Oral Prescription

Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated with Cerebral Amyloid Angiopathy

DRUG

Placebo

A placebo similar to the Jiedu Huayu Oral Prescription

Sponsors & Collaborators

• Dongzhimen Hospital, Beijing

  collaborator OTHER

• The First Hospital of Jilin University

  collaborator OTHER

• Huairou Hospital of Traditional Chinese Medicine

  collaborator OTHER

• Weihai Wendeng District Central Hospital

  collaborator UNKNOWN

• Nanyang First People's Hospital of Henan province

  collaborator UNKNOWN

• Luohe Central Hospital

  collaborator UNKNOWN

• Baofeng County People's Hospital

  collaborator UNKNOWN

• Taoyuan County People's Hospital

  collaborator UNKNOWN

• Qingdao Huangdao District Central Hospital

  collaborator UNKNOWN

• Guantao County People's Hospital

  collaborator UNKNOWN

• Lushan County Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• Yutian County Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• Xianghe County Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• Wuyuan County People's Hospital

  collaborator UNKNOWN

• Jiyuan Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• Tonghua People's Hospital

  collaborator UNKNOWN

• Beijing Tiantan Hospital

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

50 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-12-20

Primary Completion

2028-11-30

Completion

2028-11-30

Countries

• China

Study Locations